- Home
- MGTX vs MGNX Comparison
MGTX vs MGNX Comparison
Compare MGTX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- MGNX
- Stock Information
- Founded
- MGTX 2015
- MGNX 2000
- Country
- MGTX United States
- MGNX United States
- Employees
- MGTX N/A
- MGNX N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MGTX Health Care
- MGNX Health Care
- Exchange
- MGTX Nasdaq
- MGNX Nasdaq
- Market Cap
- MGTX 701.5M
- MGNX 99.7M
- IPO Year
- MGTX N/A
- MGNX 2013
- Fundamental
- Price
- MGTX $8.85
- MGNX $1.89
- Analyst Decision
- MGTX Strong Buy
- MGNX Hold
- Analyst Count
- MGTX 3
- MGNX 6
- Target Price
- MGTX $25.67
- MGNX $3.20
- AVG Volume (30 Days)
- MGTX 441.5K
- MGNX 733.9K
- Earning Date
- MGTX 11-12-2025
- MGNX 11-04-2025
- Dividend Yield
- MGTX N/A
- MGNX N/A
- EPS Growth
- MGTX N/A
- MGNX N/A
- EPS
- MGTX N/A
- MGNX N/A
- Revenue
- MGTX $37,917,000.00
- MGNX $165,495,000.00
- Revenue This Year
- MGTX $144.79
- MGNX N/A
- Revenue Next Year
- MGTX $168.58
- MGNX N/A
- P/E Ratio
- MGTX N/A
- MGNX N/A
- Revenue Growth
- MGTX 366.84
- MGNX 303.47
- 52 Week Low
- MGTX $4.55
- MGNX $0.99
- 52 Week High
- MGTX $9.44
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- MGTX 58.83
- MGNX 58.60
- Support Level
- MGTX $8.42
- MGNX $1.82
- Resistance Level
- MGTX $9.17
- MGNX $2.15
- Average True Range (ATR)
- MGTX 0.62
- MGNX 0.13
- MACD
- MGTX 0.06
- MGNX 0.02
- Stochastic Oscillator
- MGTX 70.28
- MGNX 57.63
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.